Isolated middle cerebral artery (MCA) stenosis in young patients with no other medical condition may be a unique pathologic entity with a benign long-term course. Generally, moyamoya disease shows a progression of stenosis from internal cerebral artery (ICA) to other intracranial vessel. A 26-year-old woman was admitted for choreic movements of the right arm and leg. Brain magnetic resonance imaging showed no stroke. Conventional angiography revealed 48% stenosis of the left M1 without ICA stenosis. Single photon emission computed tomography revealed perfusion asymmetry after acetazolamide injection, suggesting decreased uptake in the left basal ganglia and the cerebral cortex. Her hemichorea was mildly decreased with risperidone. One year later, follow-up angiography showed complete occlusion of the left M1 with neovascularization suggestive of moyamoya disease. The patient underwent bypass surgery and her hemichorea disappeared. This may be an atypical presentation of moyamoya disease. The bypass surgery was an effective measure for restoring the vascular insufficiency and, resultantly, controlling her hemichorea.

Citations

Citations to this article as recorded by  

• Hemichorea in patients with temporal lobe infarcts: Two case reports
  Xu-Dong Wang, Xing Li, Chun-Lian Pan
  World Journal of Clinical Cases.2024; 12(4): 806.     CrossRef
• Truncal dystonia with isolated middle cerebral artery ischemia: A case report of revascularization therapy for dystonia
  Shinichi Matsumoto, Yuki Yamamoto, Koji Fujita, Ryosuke Miyamoto, Hidetaka Koizumi, Akihiro Tateishi, Naoaki Yamada, Yuishin Izumi
  Surgical Neurology International.2022; 13: 155.     CrossRef
• Geriatric Case of Moyamoya Disease Presenting with Hemiballismus as an Initial Manifestation
  Koichiro SATO, Masaru IDEI, Kenichirou NOGAMI, Makoto KURESHIMA, Kaname HOKAO, Rina TORII, Takenori UOZUMI, Junkoh YAMAMOTO
  Surgery for Cerebral Stroke.2022; 50(6): 508.     CrossRef
• Persistent Hemichorea as a Preceding Symptom of Cerebral Infarction Due to Middle Cerebral Artery Stenosis
  Yuki Ueta, Haruhisa Kato, Makiko Naito, Takeshi Taguchi, Hiroo Terashi, Hitoshi Aizawa
  Internal Medicine.2021; 60(23): 3805.     CrossRef
• Clinical findings of a patient with hemiballism after superficial temporal artery-middle cerebral artery anastomosis for idiopathic middle cerebral artery stenosis
  Hideaki Shibata, Yuichi Hayashi, Nobuaki Yoshikura, Megumi Yamada, Akio Kimura, Takayoshi Shimohata
  Rinsho Shinkeigaku.2019; 59(12): 829.     CrossRef

Zolpidem is usually used for the treatment of insomnia as a hypnotic drug. It was also suggested to be effective in the treatment of dystonia in some studies. A 74-year-old woman had been suffering from frequent and intense bilateral spasms of the eyelids for 20 years. She has been treated with botulinum toxin injection and taken some medications. But, she experienced a little effect and was not satisfied with those treatments. Her symptom was improved after taking Zolpidem which had been prescribed for insomnia by her primary physician. She did not show any improvement after placebo injection and neostigmine test. This is the first report which shows improvement of isolated blepharospasm by Zolpidem in Korea. Zolpidem can be one of useful alternative pharmacological treatments for blepharospasm. Further randomized, blinded, placebo-controlled studies are needed to validate this finding.

Citations

Citations to this article as recorded by  

• Zolpidem for the Treatment of Dystonia
  Stephanie Patricia J. Badillo, Roland Dominic G. Jamora
  Frontiers in Neurology.2019;[Epub]     CrossRef
• Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease
  Antonio Daniele, Francesco Panza, Antonio Greco, Giancarlo Logroscino, Davide Seripa
  Parkinson's Disease.2016; 2016: 1.     CrossRef
• Medical treatment of dystonia
  Pichet Termsarasab, Thananan Thammongkolchai, Steven J. Frucht
  Journal of Clinical Movement Disorders.2016;[Epub]     CrossRef

Cerebral white matter lesions (CWMLs) have been suggested to be associated with an increased risk of dementia, disability, and death. CWMLs are more common in individuals with Alzheimer’s disease (AD) than in normal elderly individuals of comparable age. Only a few studies have been done to determine whether CWMLs may influence cognitive decline in Parkinson’s disease (PD). Fully developed PD with concurrent AD was reported to likely cause impaired cognition in spite of accumulating evidence suggesting that PD with dementia (PDD) is more closely associated with Lewy body (LB) pathology. Currently, contradictory data on the neuropathology of dementia in PD require further prospective clinicopathological studies in larger cohorts to elucidate the impact of AD and α-synuclein (SCNA) pathologies on the cognitive status in these disorders. Previous reports did not suggest CWMLs to be associated with an increased risk of PDD. After adjusting for age at death, age at onset of PD, and duration of PD, our recent study investigating CWMLs in PDD via autopsy has shown a positive correlation between the burden of CWMLs and PDD. The frequent co-existence of both LB and AD lesions suggests that both pathologies independently or synergistically contribute to both movement disorders and cognitive impairment. The individual and cumulative burden of CWMLs, LB lesions, and AD lesions may synergistically contribute to cognitive decline in LB disorders such as PDD.

Citations

Citations to this article as recorded by  

• Cx43 Mediates Resistance against MPP+-Induced Apoptosis in SH-SY5Y Neuroblastoma Cells via Modulating the Mitochondrial Apoptosis Pathway
  In-Su Kim, Palanivel Ganesan, Dong-Kug Choi
  International Journal of Molecular Sciences.2016; 17(11): 1819.     CrossRef
• Gray and White Matter Contributions to Cognitive Frontostriatal Deficits in Non-Demented Parkinson's Disease
  Catherine C. Price, Jared Tanner, Peter T. Nguyen, Nadine A. Schwab, Sandra Mitchell, Elizabeth Slonena, Babette Brumback, Michael S. Okun, Thomas H. Mareci, Dawn Bowers, Stephen D Ginsberg
  PLOS ONE.2016; 11(1): e0147332.     CrossRef
• White Matter Hypoperfusion and Damage in Dementia: Post‐Mortem Assessment
  Seth Love, J Scott Miners
  Brain Pathology.2015; 25(1): 99.     CrossRef